Neovasc

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neovasc Inc. is a specialty medical device company that develops and manufactures products for the rapidly growing cardiovascular device marketplace.Neovasc Inc. offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners.

Shockwave Medical

SANTA CLARA, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”).

Shockwave Medical, Inc. Completes Acquisition of Neovasc

SANTA CLARA, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (“IVL”) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”).

Shockwave Medical Completes Acquisition of Neovasc

VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022.

Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareholders of the Company (the "Shareholders") present in person or represented by proxy at the Meeting, and (ii) 97.21% of the votes cast by Shareholders, other than those Shareholders required to be excluded pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions, present in person or represented by proxy at the Meeting.

Neovasc Shareholders Approve Acquisition by Shockwave Medical

This up-and-coming medical technology star is set up to deliver market-beating gains for its long-term investors.

A Bull Market Is Coming: 1 Outstanding Growth Stock Down 36% to Buy and Hold

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 1, 2023) - Neovasc, Inc. (NASDAQ : NVCN) (TSX : NVCN) ("Neovasc" or "the Company") today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023.

Neovasc Announces German Reimbursement Renewal

AstraZeneca

BioNTech SE

CVS Health

Gilead Sciences

LHC Group

Leap Therapeutics

Moderna

Signify Health

Sanofi

UnitedHealth Group

Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $6 billion sale of LHC Group Inc. (Nasdaq: LHCG) to UnitedHealth (NYSE: UNH) and the $8 billion sale of Signify Health Inc. (NYSE: SGFY) to CVS Health Co. (NYSE: CVS).

Mergers and Acquisitions in 2023 Off To A Strong Start

Neovasc announced that it is being acquired by Shockwave Medical. These are the details.

Shockwave Medical To Buy Neovasc: Details (NVCN)

Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entered into a binding agreement (the "Arrangement Agreement") with Shockwave Medical, Inc. ("Shockwave"), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the "Common Shares") of the Company (the "Transaction").

Shockwave Medical to Acquire Neovasc

Neovasc (NVCN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Neovasc (NVCN) is on the Move, Here's Why the Trend Could be Sustainable

Neovasc (NVCN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in Neovasc (NVCN) is Your Friend, Here's Why

Tactile Systems

Veracyte

Here we discuss three medical instruments stocks - TCMD, VCYT and NVCN - that have started to recover in the past few months after declining for the major part of 2022.

3 Medical Instruments Stocks on Recovery Path After Dismal 2022

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced an update on the COSIRA-II Clinical Trial ("Trial") status. COSIRA-II is the U.S. Investigational Device Exemption ("IDE") pivotal clinical trial the Company is executing for the Neovasc Reducer™ ("Reducer") towards an approval decision for the device in the United States.

Neovasc Announces Progress on COSIRA-II Clinical Trial

VANCOUVER and MINNEAPOLIS, Nov. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that European Heart Journal - Case Reports has published an article titled, “Implantation of the Coronary Sinus Reducer for Refractory Angina due to Coronary Microvascular Dysfunction in the Context of Apical Hypertrophic Cardiomyopathy – a Case Report.” The article is authored by Dr. Kevin Cheng, et al, at the National Heart and Lung Institute Imperial College London, Royal Brompton Hospital, London.

Neovasc Comments on European Heart Journal Publication

Neovasc (NVCN) delivered earnings and revenue surprises of -6.38% and 7.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Neovasc (NVCN) Reports Q3 Loss, Misses Revenue Estimates

Neovasc Inc. (NASDAQ:NVCN ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Mike Cavanaugh - Investor Relations Fred Colen - President & Chief Executive Officer Chris Clark - Chief Financial Officer Conference Call Participants David Martin - Bloom Burton Operator Good day, and welcome to the Neovasc Incorporated Third Quarter Earnings Call. At this time, I will turn the call over to Mark Cavanaugh.

Neovasc Inc. (NVCN) Q3 2022 Earnings Call Transcript

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 10, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the third quarter ended September 30, 2022.Recent HighlightsGenerated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third quarter of 2021.Accelerating acceptance of Reducer in the UK and French markets, with France the largest volume market in the quarter.

Neovasc Announces Third Quarter Financial Results and Provides Corporate Update

VANCOUVER and MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc  Inc. (“Neovasc” or the “Company”) ( NASDAQ ,  TSX : NVCN) today announced that the Centers for Medicare and Medicaid Services (“CMS”) has assigned the Neovasc Reducer™ (“Reducer”) implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for the device and implant procedure.

Neovasc Reducer Obtains U.S. Outpatient Reimbursement

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 27, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm ET on November 10, 2022.

Neovasc to Report Third Quarter Financial Results on November 10, 2022

New Data Presented on the Neovasc Reducer™ in Patients With Microvascular Disease

Neovasc Provides Corporate Update Following Clinical Data Release

VANCOUVER and MINNEAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc.  (Neovasc or the Company) (  NASDAQ  ,  TSX  : NVCN) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in Hertfordshire, United Kingdom on September 21-24, 2022.

Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit

VANCOUVER and MINNEAPOLIS, Sept. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today commented on the Centers for Medicare and Medicaid Services (“CMS”) development of new codes for the diagnosis and tracking of refractory angina. The new codes will be utilized in the current, 10th revision of the International Statistical Classification of Diseases and Related Health Problems Clinical Modification (“ICD-10-CM”). The latest update was published in the ICD-10-CM Tabular List of Diseases and Injuries 2023 Addenda and will be effective October 1, 2022.

Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina

VANCOUVER and MINNEAPOLIS, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced its participation and presence at the Transcatheter Cardiovascular Therapeutics TCT 2022 conference (“TCT”), hosted by the Cardiovascular Research Foundation (“CRF”), taking place in person at the Boston Convention & Exhibition Center, September 16-19, 2022. Members of the Neovasc team will be available at booth 647 in the exhibit hall.

Neovasc Announces Key Events at TCT 2022

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 30, 2022) - Neovasc, Inc. (Neovasc or the Company) (NASDAQ: NVCN) (TSX: NVCN) today announced that its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022, in New York City. Neovasc's President and Chief Executive Officer, Fred Colen, will be presenting at 1:30 pm ET on Tuesday, September 13, 2022.

Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference

Neovasc Inc. (NASDAQ:NVCN ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Mike Cavanaugh - Investor Relations Fred Colen - President and Chief Executive Officer Chris Clark - Chief Financial Officer Conference Call Participants Vernon Bernardino - H. C. Wainwright Operator Greetings and welcome to Neovasc Inc Second Quarter 2022 Earnings Call.

News for Neovasc Stock (NVCN)